Clinical trialPhase 2Terminated
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
- Outcome
- Stopped earlyExtreme toxicity of Pertuzumab and Erlotinib combination (Toxicity)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- July 2010
- Expected end
- March 2011
- Enrollment
- 1 participants
- Sites
- 1
- Primary outcomes
- Overall Response Rate by RECIST Criteria
- Sponsor
- Other
- Results posted
- 2017-03-03
- Last update
- 3 March 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma
Detailed description public domain (ClinicalTrials.gov)
A single-institution, single-arm phase 2 study investigating pertuzumab and erlotinib as a palliative regimen in the treatment of locally-advanced or metastatic pancreatic adenocarcinoma.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Response Rate by RECIST Criteria [CT imaging every 9 weeks while on protocol]. Pertuzumab Plus Erlotinib Hydrochloride (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival (PFS) [9 weeks]. Pertuzumab Plus Erlotinib Hydrochloride (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival (OS) [1 year]. Pertuzumab Plus Erlotinib Hydrochloride (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Quality of Life (QoL) [3 weeks]. Pertuzumab Plus Erlotinib Hydrochloride (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
No. of Events of Drug-related Toxicity [3 weeks]. Number, Drug-related adverse events. Pertuzumab Plus Erlotinib Hydrochloride (n=1): 3.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Proportion of Participants With 50% Decrease in Tumor Marker [3 weeks]. Pertuzumab Plus Erlotinib Hydrochloride (n=0): 0.